Relaxation of IGF2 imprinting occurs in Wilms tumours and many other cancers, but the mechanism of loss of imprinting (LOI) remains unknown. To investigate the role of altered DNA methylation in LOI, we examined the pattern of methylation of the human insulin-IGF2 region in Wilms tumours and the normal kidney. The analysis included regions homologous to three`dierentially methylated regions' of the mouse Igf2 gene (dmrs 0, 1 and 2). In tumours displaying normal IGF2 imprinting, and in the normal kidney, maternal allelespeci®c DNA methylation was identi®ed spanning exons 2 and 3. This region is homologous to dmr 0, a site of maternal-speci®c dierential methylation in the mouse. In Wilms tumours with relaxed imprinting or 11p15.5 LOH this region was unmethylated. No other dierential methylation was identi®ed. In particular, two sites of paternal methylation in the mouse (dmrs 1 and 2), and all three imprinted IGF2 promoters were not methylated in the kidney or in Wilms tumours. We postulate that LOI in Wilms tumours is associated with loss of maternal allele-speci®c methylation from a region located upstream of the imprinted IGF2 promoters. This region may contain cis acting sequences that coordinately in¯uence imprinting.
Introduction
Genomic imprinting describes the modi®cation of a gene, or a chromosome region by the parental gonad such that only one allele of the gene is expressed (Efstratiadis, 1994) . IGF2 and H19 are two imprinted genes located adjacent to each other at 11p15.5, a region which is frequently involved in cancer. In the case of IGF2 gene, only the paternally inherited allele is expressed while the maternal allele is silent (Giannoukakis et al., 1993; Ohlsson et al., 1993) . The H19 gene is oppositely imprinted and is expressed from only the maternal allele (Goshen et al., 1993; Zhang et al., 1993) .
In Wilms tumour and many other childhood and adult cancers the imprinting of IGF2 is relaxed, that is the normally silent maternal allele becomes active and the gene is biallelically expressed (Ogawa et al., 1993; Rainier et al., 1993 Rainier et al., , 1995 Pedone et al., 1994; Suzuki et al., 1994; van Gurp et al., 1994; Zhan et al., 1994; Hashimoto et al., 1995 Hashimoto et al., , 1997 Douc-Rasy et al., 1996; Hibi et al., 1996; McCann et al., 1996; Kim and Lee, 1997; Nonomura et al., 1997; Wu et al., 1997; Oda et al., 1998; Randhawa et al., 1998) . The same phenomenon of relaxed IGF2 imprinting commonly occurs in Beckwith-Wiedemann syndrome (Weksberg et al., 1993; Reik et al., 1994) , in children with the constitutional IGF2 overgrowth syndrome (Morison et al., 1996) , and in the normal tissue adjacent to some cancers with relaxed imprinting (Okamoto et al., 1997; Cui et al., 1998) .
The molecular events involved in relaxation of IGF2 imprinting (LOI) in cancer have not been determined, and it is not yet clear whether epigenetic events such as altered DNA methylation are directly involved in LOI. We and others have previously shown that biallelic IGF2 expression in Wilms tumours is accompanied by de novo methylation and silencing of the maternal H19 allele (Moulton et al., 1994; Steenman et al., 1994; Taniguchi et al., 1995b) .
This pattern of IGF2 and H19 expression and imprinting in Wilms tumours lends support to the enhancer competition hypothesis which suggests there is a mechanistic relationship in the imprinting of the mouse Igf2 and H19 genes (Leighton et al., 1995a,b) . However, it is unclear whether a similar model applies to regulation of the human IGF2 and H19 genes because in several dierent types of solid tumour and in some cases of Beckwith-Wiedemann syndrome, there is no reciprocal pattern of IGF2 and H19 expression (van Gurp et al., 1994; Hashimoto et al., 1995 Hashimoto et al., , 1997 Douc-Rasy et al., 1996; Hibi et al., 1996; Kim and Lee, 1997; Joyce et al., 1997) .
Previous methylation studies of the mouse Igf2 gene have identi®ed three dierentially methylated regions (dmrs) (Moore et al., 1997) . Two of these regions, dmr 0 and dmr 1, are located upstream of exon 1 of mouse Igf2; dmr 0 is methylated on the inactive maternal allele, while dmr 1 is methylated on the active paternal allel (Figure 1) . A third region in the mouse, dmr 2, is located within the last coding exon (exon 6) and shows methylation on the active paternal allele (Feil et al., 1994) . The mouse Igf2 promoters were previously shown to have no allele-speci®c methylation (Sasaki et al., 1992) .
Compared to the studies of Igf2 methylation in the mouse, investigations of human IGF2 have been more limited and focused only on two regions. Firstly, the human IGF2 promoter complex was found to be unmethylated in cell lines (Eversole-Cire et al., 1993) and in another study the IGF2 promoter region acquired de novo methylation in the colonic epithelium of ageing individuals (Issa et al., 1996) . Secondly, a region of allele-speci®c methylation similar to the mouse dmr 2 was identi®ed within exon 9 on the active paternal allele in peripheral blood DNA (Schneid, 1993; Reik et al., 1995) . In an earlier report of Wilms tumours we found evidence for allele-speci®c methylation of IGF2 in Wilms tumours with normal IGF2 imprinting. However the IGF2 gene appeared to be completely unmethylated in those Wilms tumours with relaxed IGF2 imprinting (Taniguchi et al., 1995b) .
Here we report a detailed analysis of the pattern of methylation of the entire human IGF2 gene, to determine whether speci®c alterations in DNA methylation are associated with relaxation of IGF2 imprinting. Wilms tumours provided an ideal tumour to investigate this question because they demonstrate relaxed IGF2 imprinting (Ogawa et al., 1993; Rainier et al., 1993) at a high frequency and express IGF2 at high levels (Reeve et al., 1985) . Furthermore, because approximately one third of Wilms tumours lose maternal alleles from the chromosome 11p15.5 region, methylation patterns may be readily assigned to the remaining paternally derived IGF2 gene.
We have also compared the pattern of methylation in the human IGF2 to that previously found in the mouse Igf2 gene, and have identi®ed a region of speci®c methylation which may contain DNA sequences that act in cis to control IGF2 imprinting.
Results
The structure of the human, and mouse IGF2 genes In order to study methylation of IGF2, it was ®rst necessary to complete the DNA sequence and structure of the human insulin-IGF2 gene region (Figure 1 ). Several gaps between previously reported DNA sequences were sequenced using the human IGF2 cosmid, cos-IGF2. A 36 kilobase DNA sequence extending from the human insulin gene to the 3' end of IGF2 was assembled with the following accession numbers; 5' -L155440 -U80849 -X03423 -U80850 -M22372 -U80851 -X53038 -X03562 -X07868-3' (MJ Sullivan in preparation). Figure 1 shows the location of three regions of dierential DNA methylation in mouse Igf2, designated dmr 0, dmr 1 and dmr 2. The human IGF2 gene has four promoters P1-P4 which are located 5' to exons 1, 4, 5 and 6 respectively, whereas the mouse Igf2 gene has three promoters P1, P2 and P3, located 5' to exons 1, 2 and 3 respectively.
Strategy for methylation analysis of IGF2
The IGF2 expression status of the Wilms tumours used in this study was determined by RT ± PCR and has been reported previously (Ogawa et al., 1993; Taniguchi et al., 1995b) .
Methylation of IGF2 was investigated using the DNA methylation-sensitive enzyme HpaII and its Figure 1 The structure of the human and mouse IGF2 genes. The human IGF2 gene is shown together with the mouse IGF2 gene structure. The sequence of the human IGF2 gene region was completed by sequencing the human IGF2 cosmid, cos-IGF2, and a 36 kb DNA sequence assembled with the following accession numbers; 5'-L155440-U80849-X03423-U80850-M22372-U80851-X53038-X03562 X07868-3' (in preparation). The location of MspI sites in both the mouse and human genes are indicated by lower vertical lines. The DNA methylation probes used for Southern blot analysis of DNA methylation are also shown. Three regions of dierential DNA methylation have been identi®ed in the mouse IGF2 gene, designated dmr 0, dmr 1 and dmr 2. The human gene has four promoters P1 ± P4 which are located 5' to exons 1, 4, 5 and 6 respectively (arrows). The mouse gene has three promoters P1, P2 and P5, located 5' to exons 1, 2 and 3 respectively (arrows). The mouse gene contains two pseudo-exons (C1 and C2) homologous to human IGF2 exons 2 and 3. Two repetitive sequences, repeat 1 and 2, in the mouse Igf2 gene are shown, no similar sequences were found in the human IGF2 gene isoschizomer MspI, in the normal kidney, and in tumours with normal imprinted IGF2 expression, with LOH at 11p15.5, and in tumours with relaxed imprinting. Southern blots prepared and serially hybridized with multiple IGF2 DNA probes as shown in Figure 1 . Probes 1 ± 7 and 9 were¯anked by MspI/ HpaII sites resulting in a single band after digestion of DNA with MspI regardless of methylation state, or a single band after HpaII digestion if the DNA was unmethylated. Probe 8 spanned a polymorphic MspI site. Probe 4 included the short Alu sequence which resulted in a high background due to cross hybridization with other Alu sequences. Probes 11, 12 and 13 hybridize to the large CpG island spanning exons 4, 5 and 6, and include the imprinted promoters P2, P3 and P4, respectively. Since this region is CpG rich and has many MspI sites, Southern blots with these probes showed hybridization to single large MspI fragments because all the other MspI fragments within this region were too small to resolve on electrophoresis. If IGF2 had been methylated at these sites, DNA fragments larger than the limit MspI digest would have been seen.
Methylation analysis from exon 1 to exon 2 in normal kidney and Wilms tumours
An analysis of the pattern of methylation of the human IGF2 gene in normal human kidney and Wilms tumours is shown in Figure 2 . This ®gure shows the pattern of methylation at dierent sites of IGF2 in a 5' 
Methylation analysis of exon 2 to exon 3 region in the normal kidney and Wilms tumours
The region of the human IGF2 gene spanning exons 2 and 3 is homologous to the mouse dmr 0. This region showed a pattern of methylation which was distinctly dierent between the three groups of tumours. Figure  2a .5 LOH, were also unmethylated over this region suggesting that the retained (expressed) paternal IGF2 allele was unmethylated (Figure 2b, probe 8) . From these results we can infer that relaxation of IGF2 imprinting is associated with a loss of methylation from the maternal IGF2 allele. This is in keeping with our previous study which demonstrated that Wilms tumours with monoallelic IGF2 expression were methylated on the inactive maternal allele (Taniguchi et al., 1995b) .
To localize the region of dierential methylation around exons 2 and 3, Southern blots were prepared using DNA from all three groups of Wilms tumours using restriction enzyme digestion either with PstI alone, or double restriction digestion with PstI and HpaII, or PstI and MspI and hybridized with IGF2 probes 7, 8 and 9. Restriction digestion with PstI alone produced a 3.2 kb fragment spanning exons 2 and 3, which included ten MspI restriction sites. Figure 3a ± c con®rmed the partial methylation pattern seen in monoallelic Wilms tumours while tumours with 11p15.5 LOH, and relaxed IGF2 imprinting, were unmethylated.
The allele speci®city of this methylation pattern was investigated using probe 8, which encompasses a polymorphic MspI site with fragment sizes of 390+100 bp and 490 bp (arrowhead in Figure 3a ± c, probe 8). Two of the tumours with monoallelic IGF2 expression were informative as shown by the presence of two bands on digestion with MspI. After digestion with HpaII, the 390 bp allele (arrowhead) was absent indicating that one allele was methylated while the other allele was unmethylated. Furthermore in tumours with 11p15.5 LOH the retained paternal allele was unmethylated (arrowhead in Figure 3c ), whereas tumours with biallelic IGF2 expression were unmethylated on both alleles (Figure 3b ). These data indicate that expression from the maternal IGF2 allele is associated with the methylation in a discrete region spanning exons 2 and 3.
To ensure that this methylation pattern in Wilms tumours was not due to partial restriction enzyme digestion the Southern membranes were analysed with a probe for mitochondrial DNA which copuri®es with Wilms tumours with biallelic IGF2 expression. Wilms tumours with monoallelic IGF2 expression show an allele-speci®c pattern of methylation whereas this region is unmethylated in Wilms tumours with 11p15.5 LOH and biallelic IGF2 expression. Two tumours with monoallelic IGF2 expression were polymorphic for an MspI polymorphism (probe 8). When digested with HpaII, only one unmethylated allele was seen indicating that this region has allele-speci®c methylation. These Southern ®lters were stripped and rehybridized with a mitochondrial probe. This identi®es a single 3.0 kb mitochondrial DNA fragment and a 900 bp MspI DNA fragment. Complete digestion of the mitochondrial DNA with MspI and HpaII excludes partial restriction digestion genomic DNA and is unmethylated. The mitochondrial probe chosen detects a 2.1 kb mitochondrial PstI fragment and a single 900 bp HpaII fragment. Digestion with MspI and HpaII gave a single 900 bp mitochondrial fragment indicating that restriction enzyme digestion was complete.
Methylation analysis from exon 3 to exon 6 in the normal kidney and Wilms tumours
The region of the human IGF2 gene between exon 3 and exon 4 is homologous to a region of paternal allele-speci®c methylation in the mouse IGF2 gene designated dmr 1 (Feil et al., 1994) . This region was studied using DNA probes 9 and 10 ± 13. Figure 2a ± d shows that the region of IGF2 from exon 3 to exon 6 was unmethylated in all three groups of Wilms tumours and in the normal kidney irrespective of the IGF2 expression status. Additional probes between 9 and 10 were also unmethylated in the kidney and all tumours (data not shown). Probes 11, 12 and 13 span the large CpG island which contains the three imprinted promoters P2 ± P4. All three imprinted IGF2 promoters were unmethylated in all Wilms tumours and the normal kidney (Figure 2a ± d, probes 12 and 13).
Methylation of exon 7 to exon 9 in the normal kidney and Wilms tumours
In contrast to the maternal allele-speci®c methylation shown in exons 2 and 3, two previous reports identi®ed paternal allele-speci®c methylation at exon 9 in peripheral blood lymphocyte DNA of normal individuals, and in patients with the Beckwith-Wiedemann syndrome (Schneid, 1993; Reik et al., 1995) . This region is homologous to mouse Igf2 dmr 2, a site of paternal allele-speci®c methylation. To investigate methylation of exons 7, 8 and 9 in normal kidney and Wilms tumour, a DNA methylation analysis was done using the method previously reported by Schneid et al., (1993) . The relevant restriction map of exons 6 ± 9 is shown in Figure 4 . DNA from paired normal kidney and Wilms tumour was digested with AvaII and double digested with AvaII and HpaII.
In Figure 4b ± d, lane 1, two polymorphic alleles are present (arrowhead, 0.9 kb and 1.1 kb) indicating that each normal kidney was polymorphic for the exon 9 AvaII restriction site. When normal kidney DNA was digested with HpaII both polymorphic bands were digested showing that the region was unmethylated on both alleles in these kidneys (Figure 4b fragment derived from the retained paternal allele was present (Figure 4b , lane 3) and on digestion with HpaII this allele was found to be unmethylated (Figure 4b , lane 4). In Wilms tumour with monoallelic IGF2 expression, and those with LOI, both the paternal and maternal IGF2 alleles were unmethylated ( Figure  4c,d, lane 4) . Hence, in the normal kidney and in Wilms tumour, methylation of the 3' part of IGF2 was not necessary for either IGF2 imprinting or IGF2 expression. However, we did ®nd that exon 9 was methylated in peripheral blood leukocytes which suggests the 3' end of IGF2 is a region of tissue speci®c DNA methylation (data not shown).
Discussion
We have used Wilms tumours and normal human kidney to investigate the relationship between DNA methylation and relaxation of IGF2 imprinting. In Wilms tumours with biallelic IGF2 expression, the maternal H19 allele has been shown to acquire, a paternal methylation epigenotype (Moulton et al., 1994 , Steenman et al., 1994 , Taniguchi et al., 1995b . In addition, we also showed the maternal IGF2 allele was hypomethylated in tumours with LOI (Taniguchi et al., 1995b) . Unlike other cancers which have a generalized alteration in methylation, these methylation changes in Wilms tumour appear to be con®ned to the IGF2/H19 locus (Taniguchi et al., 1995b) .
The methylation analysis reported here has spanned the entire 36 kb of the human Ins-IGF2 gene region. We have shown that relaxation of IGF2 imprinting in Wilms tumours is accompanied by loss of methylation from the maternal allele in a region spanning 2 kb of DNA located upstream of the imprinted promoter complex. This region is homologous to a region of maternal allelespeci®c methylation (dmr 0), previously identi®ed in the mouse IGF2 gene (Moore et al., 1997) . Analysis of the remainder of the IGF2 gene identi®ed no other regions of dierential methylation. In particular, two regions of dierential methylation on the paternal allele of the mouse Igf2 gene which have been associated with imprinting (dmr 1 and dmr 2), were found to be unmethylated in the normal kidney and in Wilms tumours regardless of the state of IGF2 imprinting. We also show here that the CpG island which contains the three imprinted IGF2 promoters were biallelically unmethylated in Wilms tumours and in the normal kidney regardless of the IGF2 expression status.
Our ®nding of loss of imprinting associated with loss of maternal allele-speci®c methylation is in agreement with Eversole-Cire et al. (1993) who examined the methylation of the mouse Igf2 gene in cells disomic for the imprinted maternal allele. Treatment of these cell lines with the demethylating agent 5-azacytidine increased Igf2 expression from the imprinted maternal allele. In a similar analysis of the mouse and human IGF2 genes in astrocyte cell lines, Hu et al. showed that treatment with 2-deoxy-5-azacytidine, caused relaxation of IGF2 imprinting (Hu et al., 1997a) . Hence in these studies relaxation of IGF2 imprinting of both the mouse and the human IGF2 genes was associated with hypomethylation.
However these studies, and the results reported here are at variance with the previous methylation data from other groups of both the mouse and human IGF2 genes. Sasaki et al. (1992) identi®ed a region of dierential methylation (dmr 1) on the active paternal allele located upstream of mouse exon 1. This region of dierential methylation was later mapped in detail by the bisulphite technique and showed that the paternal mouse Igf2 allele was relatively more methylated than the maternal allele (Feil et al., 1994) . In contrast we have shown that the homologous region of the human IGF2 gene (between exons 3 and 4) was unmethylated on both alleles in normal kidney and Wilms tumours. As already noted above, another region of dierential methylation (dmr 0) in the mouse Igf2 gene was recently identi®ed on the maternal allele near the mouse pseudo-exon 2 (Moore et al., 1997) . We have shown that the homologous region in the human is also methylated on the maternal allele and that loss of imprinting is associated with loss of methylation from this region. Our data is also at variance with the DNA methyltransferase (dnmt) knockout experiments which have shown down regulation of Igf2 in the mouse with methyltransferase de®ciency (Li et al., 1993) .
In previous methylation studies of the human IGF2 gene by Schneid et al. (1993) and Reik et al. (1994) , dierential methylation was identi®ed on the active paternal allele at exon 9 in peripheral blood lymphocytes from normal individuals and patients with the Beckwith-Wiedemann syndrome. In a similar analysis of this region, we have shown the exon 9 region to be biallelically unmethylated in the normal kidney and in Wilms tumours regardless of the expression state of IGF2 imprinting. Thus methylation of the paternal IGF2 allele at exon 9 in peripheral blood most likely represents a site of tissue speci®c methylation which is not involved in IGF2 imprinting.
Since relaxation of IGF2 imprinting is accompanied by biallelic expression of all three imprinted IGF2 promoters, this suggests that loss of imprinting must collectively disrupt repression of the maternal allele promoters (Taniguchi et al., 1995a; Vu and Homan, 1996) . Given that the only allelic dierence in IGF2 methylation was located upstream of the imprinted promoters it is conceivable that this region has a cisacting methylation centre similar to those previously identi®ed in the mouse Aprt gene and the Igk locus (Mummaneni et al., 1993 (Mummaneni et al., , 1995 Kirillov, 1996) . A candidate imprinting element located upstream of the Igf2 gene has been identi®ed in the mouse which when deleted from the maternal allele leads to activation of the maternal Igf2 gene (Hu et al., 1997b) .
While this methylation study was con®ned to the human IGF2 gene, the ®ndings are also of more general signi®cance to our understanding of imprinting because of the postulated role for DNA methylation in the IGF2/H19 enhancer hypothesis, which has been proposed to account for the coordinate relationship between IGF2 and H19 imprinting. In this model control of IGF2 and H19 imprinting is determined by access of each gene to regional enhancer elements located down stream of H19. Methylation of the paternal H19 allele represses its expression so limiting access to the adjacent enhancers, whereas methylation of the paternal IGF2 allele is presumed to permit access to the enhancer sequences. Conversely on the maternal allele H19 is unmethylated allowing it to compete in cis for the enhancers leading to repression of the maternal Igf2 allele. (Leighton et al., 1995a,b) . The presence of paternal allele-speci®c methylation on both the mouse and human IGF2 genes, has lent support to this model (Schneid, 1993 ), but we show here that the only site of allele-speci®c methylation of the human IGF2 gene was present on the maternal allele not the paternal allele.
Although there is a reciprocal pattern of IGF2 and H19 expression in Wilms tumours there are many examples of tumours where this relationship does not hold (van Gurp et al., 1994; Douc-Rasy et al., 1996; Hibi et al., 1996) . It is also relevant to note that in the mouse the reciprocity of Igf2 and H19 expression in the enhancer deletion studies was con®ned to endodermally derived tissues (Leighton et al., 1995b) . These results raise the possibility of additional and independent mechanisms for the regulation of IGF2 and H19 imprinting and it remains to be seen whether the maternal allele-speci®c methylation identi®ed here is involved in other tissues and tumours.
Materials and methods

LOH analysis and IGF2 expression
Allele-speci®c expression of IGF2 and 11p15.5 LOH was determined as previously described (Ogawa et al., 1993; Taniguchi et al., 1995b) . Three Wilms tumour groups were identi®ed for comparative methylation analysis: (i) Seven Wilms tumours were studied with no 11p15.5 LOH and monoallelic IGF2 expression; (ii) Four Wilms tumours were studied with 11p15.5 LOH and IGF2 expression from the retained paternal allele; and (iii) Five Wilms tumours were studied with retention of heterozygosity and relaxation of IGF2 imprinting. Normal kidney samples were collected from normal kidney tissue adjacent to the Wilms tumours studied.
Southern blotting
Five micrograms of DNA from normal kidney, or Wilms tumour was digested in the appropriate restriction buer overnight with HpaII (10 U/mg) or MspI (5 U/mg). For PstI/ HpaII and PstI/MspI double digests, DNA was ®rst digested with HpaII or MspI, followed by digestion with PstI. Digested DNA was electrophoresed in 1.5% agarose and transferred to Hybond N + (Amersham) and UV cross-linked. All ®lters were hybridized at 658C in hybridization buer (Church and Gilbert 1984) , washed once at 658C with 26SSC/0.5% SDS and twice with 0.16SSC/0.5% SDS. Southern blots were imaged by a Fuji Bas 1500 phosphorimager.
DNA methylation analysis and probes
The human IGF2 cosmid cos-IGF2, was sequenced by primer extension using an automated DNA sequencer (ABI 377). Three new DNA sequences with GenBank accession numbers U80849, U80850 and U80851 were compiled with previously reported DNA sequences into a 36 kilobase DNA sequence extending from the human insulin gene to the 3' end of IGF2. The accession numbers for this compiled sequence are; 5'-L155440-U80849-X03423-U80850-M22372-U80851-X53038-X03562 X07868-3' (MJ Sullivan in preparation).
DNA probes (1 ± 10 and 13) were prepared by PCR from cos-IGF2 (kindly provided by Dr Holthuizen). PCR primers are listed below. Each probe was designed to bē anked by MspI sites, or where it spanned several MspI restriction sites, the PCR product was digested with MspI and the probe fragment for Southern hybridization was puri®ed from low melting point agarose. In the latter case, the Southern blots show a single hybridizing MspI fragment (or a single unmethylated HpaII fragment). Probes 11 and 12 were cosmid EcoRI fragments of 2.7 kb and 1.3 kb respectively. Probe 8 spans a polymorphic MspI site. Probe 10 spanned multiple MspI sites of a CpG island. DNA probes were labelled by random priming with [ 32 P]dCTP using the Rediprime kit (Amersham) ( Table 1) .
Mitochondrial DNA as methylation restriction enzyme digest control
A mitochondrial DNA probe was prepared by PCR from human genomic DNA using primers from the following location on the mitochondrial genome: Forward ± 7178 ± 7198; Reverse ± 7840 ± 7862. The 662 bp PCR product was digested with MspI to remove a small terminal 22 bp fragment which contained the only MspI site in the probe and the remaining 640 bp fragment used as a probe. Southern blots were stripped with boiling 0.5% SDS and rehybridized with 32 P-labelled mitochondrial DNA probe.
Abbreviations IGF2, insulin-like growth factor 2; kb, kilobase; PCR, polymerase chain reaction; dmr, dierentially methylated region; LOI, loss of imprinting; LOH, loss of heterozygosity Table 1   Probe  5 Forward 3  5 Reverse 3   1  2  3  4  5  6  7  8  9  10  13   CAACAAGGCCGTAGGGAGTGAT  TGACCCCCTTCCCAGCCCATCT  AGGGGTCTTTGCAGCTCTTTCA  CATTGATTTTGTGCCAGAGGT  TGCACCCCAGTTTTTGTCCAT  TCTTTGTTTTGTGCCTTCTCT  CACTCCCCACCACCTCCACAT  CCTCTTTCTCCACTGTCCAGGA  CCCAGGGGCCGAAGAGTCA  CCCTGAAAATTCGCTTGGAGAG  CCCGCTCTGCCCCGTCGCACATTC   GGGGGATGGAGGGGCGATACC  GGTGCCCAGCCCTCCCTCTCT  CTGGGAGGACTCTGGGGTTTT  CCGCAATTTGGGGCACTCTG  GAGAAGCGGTCAGGATAGAAA  GACGTGGAGGAGGAGAGGGAC  GACGTGGAGGAGGAGAGGGAC  TTTCTCCTCAGTCTCCTGTCCAA  GCTGAGCTGGCAGCGATTCAG  CCCGTCGAAATGGTGAATA  AGCCTTCTGCTGAGCTGTAGG 
